Applying Lessons Learned from Developing Exon Skipping for Duchenne to Developing Individualized Exon Skipping Therapy for Patients with Neurodegenerative Diseases
Antisense oligonucleotides (ASOs) are short, modified pieces of DNA that are chemically modified. They can be used to induce exon skipping and treat Duchenne muscular dystrophy (DMD) patients by interfering with the splicing process so mutated dystrophin transcripts become readable allowing production of partially functional dystrophin proteins, rather than nonfunctional dystrophins. After over 2 decades of research, 4 ASOs are FDA approved for DMD, but clinical effects are suboptimal due to limited delivery to skeletal muscle. At the same time, ASOs for brain diseases result in much more functional impact, because local delivery allows higher exposure to the target tissue at a low dose and infrequent treatment regimen. This has opened the way to develop ASOs in an individualized setting, as was exemplified by the development of Milasen to treat a patient with CLN7 Batten disease. In this perspective paper I will share my personal journey as one of the pioneers of ASO-mediated exon skipping development for DMD, currently applying expertise gained and lessons learned along the way to develop exon skipping ASOs for eligible patients with genetic brain diseases in a national and international setting. 1 Duchenne and Antisense-Mediated Exon Skipping 2 Opportunities for Treating Central Nervous System Diseases and Developing Individualized ASOs for Central Nervous System Diseases 3 Collaborative Spirit to Develop Individualized Treatments Globally 4 Global Implementation 5 Concluding Remarks
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Applying Lessons Learned from Developing Exon Skipping for Duchenne to Developing Individualized Exon Skipping Therapy for Patients with Neurodegenerative Diseases ; day:19 ; month:12 ; year:2023
Synlett ; (19.12.2023)
- Beteiligte Personen und Organisationen
- DOI
-
10.1055/a-2211-6490
- URN
-
urn:nbn:de:101:1-2024020111234504477155
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
Ähnliche Objekte (12)
Exon skipping for DMD
Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model
Elevated nuclear TDP-43 induces constitutive exon skipping
Exon skipping as a therapeutic strategy in dysferlinopathy
Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
Unexpected consequences: exon skipping caused by CRISPR-generated mutations
CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
The dilemma of choice for duchenne patients eligible for Exon 51 skipping the European experience
A compatible exon-exon junction database for the identification of exon skipping events using tandem mass spectrum data
Exon skipping for DMD
Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model
Elevated nuclear TDP-43 induces constitutive exon skipping
Exon skipping as a therapeutic strategy in dysferlinopathy
Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
Unexpected consequences: exon skipping caused by CRISPR-generated mutations
CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
The dilemma of choice for duchenne patients eligible for Exon 51 skipping the European experience
A compatible exon-exon junction database for the identification of exon skipping events using tandem mass spectrum data
Exon skipping for DMD
Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model
Elevated nuclear TDP-43 induces constitutive exon skipping
Exon skipping as a therapeutic strategy in dysferlinopathy
Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
Unexpected consequences: exon skipping caused by CRISPR-generated mutations
CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
The dilemma of choice for duchenne patients eligible for Exon 51 skipping the European experience